智通财经APP获悉，再鼎医药(09688)涨近4%，截至发稿，涨3.75%，报19.38港元，成交额1407.47万港元。
消息面上，再鼎医药宣布，全球3期innovaTV 301研究中国亚组的主要结果显示，与化疗相比，维替索妥尤单抗对于在之前接受过治疗的复发或转移性宫颈癌患者中，显示出具有临床意义的总生存期改善。再鼎医药计划在2025年第一季度向国家药品监督管理局提交维替索妥尤单抗的新药上市申请。如果获批，再鼎医药将利用尼拉帕利在女性肿瘤的商业化布局将维替索妥尤单抗惠及中国患者。
此前1月10日，再鼎医药公告称，与Vertex Pharmaceuticals Incorporated达成独家合作和许可协议，获得在大中华区和新加坡开发和商业化Povetacicept(简称Pove)的权益。中金表示，公司已通过艾加莫德的成功商业化成果验证了其在自免领域的销售能力，因此该行对Pove的未来国内商业化潜力持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.